ZA201902933B - Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy - Google Patents

Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy

Info

Publication number
ZA201902933B
ZA201902933B ZA2019/02933A ZA201902933A ZA201902933B ZA 201902933 B ZA201902933 B ZA 201902933B ZA 2019/02933 A ZA2019/02933 A ZA 2019/02933A ZA 201902933 A ZA201902933 A ZA 201902933A ZA 201902933 B ZA201902933 B ZA 201902933B
Authority
ZA
South Africa
Prior art keywords
nephropathy
immunoglobulin
methods
human subject
subject suffering
Prior art date
Application number
ZA2019/02933A
Other languages
English (en)
Inventor
Nigel John Brunskill
Gregory A Demopulos
Tom Dudler
Hans-Wilhelm Schwaeble
Original Assignee
Univ Leicester
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/399,524 external-priority patent/US10736960B2/en
Priority claimed from US15/470,647 external-priority patent/US20170253667A1/en
Application filed by Univ Leicester, Omeros Corp filed Critical Univ Leicester
Publication of ZA201902933B publication Critical patent/ZA201902933B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276Knock-out vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21104Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/075Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/035Animal model for multifactorial diseases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54F(ab')2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Environmental Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Husbandry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2019/02933A 2016-10-13 2019-05-10 Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy ZA201902933B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662407979P 2016-10-13 2016-10-13
US15/399,524 US10736960B2 (en) 2016-01-05 2017-01-05 Methods for inhibiting fibrosis in a subject in need thereof
US15/470,647 US20170253667A1 (en) 2016-01-05 2017-03-27 Methods for inhibiting fibrosis in a subject in need thereof
US201762527926P 2017-06-30 2017-06-30
PCT/US2017/056386 WO2018071701A1 (en) 2016-10-13 2017-10-12 Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy

Publications (1)

Publication Number Publication Date
ZA201902933B true ZA201902933B (en) 2023-05-31

Family

ID=61906454

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/02933A ZA201902933B (en) 2016-10-13 2019-05-10 Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy

Country Status (18)

Country Link
EP (1) EP3525798A4 (ja)
JP (1) JP6893554B2 (ja)
KR (1) KR102348939B1 (ja)
CN (2) CN110177557A (ja)
AU (1) AU2017342428B2 (ja)
BR (1) BR112019007426A2 (ja)
CA (2) CA3210384A1 (ja)
CL (2) CL2019000909A1 (ja)
GE (1) GEP20247587B (ja)
IL (1) IL265981A (ja)
JO (1) JOP20190068A1 (ja)
MA (1) MA46541A (ja)
MX (1) MX2019004074A (ja)
PH (1) PH12019500711A1 (ja)
SG (1) SG11201902941UA (ja)
UA (1) UA126908C2 (ja)
WO (1) WO2018071701A1 (ja)
ZA (1) ZA201902933B (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419860A (zh) * 2020-03-19 2020-07-17 长春市儿童医院 一种肾小球分叶状肾病造模方法
CN115215937B (zh) * 2021-04-15 2023-05-26 上海麦济生物技术有限公司 抗人masp-2抗体及其制备方法和应用
CN117016486B (zh) * 2023-07-20 2024-05-14 上海澎立生技医药研究有限公司 一种IgA肾病合并膜性肾病的动物模型构建方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2374819T1 (sl) * 2003-05-12 2017-09-29 Helion Biotech Aps Protitelesa proteina MASP-2
US20140056873A1 (en) * 2004-06-10 2014-02-27 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7626730B2 (en) 2006-03-31 2009-12-01 Eastman Kodak Company Method of making a multilevel halftone screen
CN106390117A (zh) * 2009-10-16 2017-02-15 奥默罗斯公司 通过抑制masp‑2依赖性补体活化治疗弥散性血管内凝血的方法
WO2012100262A1 (en) * 2011-01-21 2012-07-26 Fibrogen, Inc. Therapeutic method using anti - ctgf antibody
US9644035B2 (en) * 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2694108B1 (en) * 2011-04-08 2018-06-06 University Of Leicester Methods for treating conditions associated with masp-2 dependent complement activation
KR102024016B1 (ko) * 2011-05-04 2019-11-04 오메로스 코포레이션 Masp-2 의존적 보체 활성화를 억제하는 조성물
EP2968546B1 (en) * 2013-03-15 2023-09-20 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
JP2016539919A (ja) * 2013-10-17 2016-12-22 オメロス コーポレーション Masp−2依存性補体活性化に関連した状態を治療するための方法
IL294411A (en) * 2016-01-05 2022-08-01 Omeros Corp masp-2 suppressors for use in suppressing fibrosis
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق

Also Published As

Publication number Publication date
EP3525798A1 (en) 2019-08-21
GEP20247587B (en) 2024-01-25
JP2019534271A (ja) 2019-11-28
CA3210384A1 (en) 2018-04-19
JP6893554B2 (ja) 2021-06-23
IL265981A (en) 2019-06-30
EP3525798A4 (en) 2020-07-08
NZ753260A (en) 2021-11-26
SG11201902941UA (en) 2019-05-30
CA3039927C (en) 2023-10-10
CA3039927A1 (en) 2018-04-19
MA46541A (fr) 2019-08-21
KR102348939B1 (ko) 2022-01-12
CL2019000909A1 (es) 2019-06-14
CL2019003485A1 (es) 2020-04-13
UA126908C2 (uk) 2023-02-22
BR112019007426A2 (pt) 2019-07-02
AU2017342428A1 (en) 2019-05-23
CN110177557A (zh) 2019-08-27
AU2017342428B2 (en) 2021-02-04
MX2019004074A (es) 2019-06-10
KR20190063475A (ko) 2019-06-07
JOP20190068A1 (ar) 2019-04-01
WO2018071701A1 (en) 2018-04-19
PH12019500711A1 (en) 2019-11-18
CN116726163A (zh) 2023-09-12

Similar Documents

Publication Publication Date Title
SG11201609238VA (en) Binding affinity prediction system and method
HUE053370T2 (hu) Eljárás üzemmód átkapcsolásra
PT3099946T (pt) Meio de fixação e método para fixação de dois componentes
HK1254988A1 (zh) 連接裝置和用於連接兩個部件的方法
HK1250918A1 (zh) 用於膠質母細胞瘤的egfr導向的car療法
ZA201702173B (en) Sorbent for binding metal and production thereof
IL264641A (en) Acetyl-leucine for use in the treatment of neurodegenerative diseases
PL2960001T3 (pl) Układ do spawania oraz sposób komunikacji dla układu do spawania
TWI560635B (en) System and method for rating and selecting models
GB201607767D0 (en) Welding method
SG11201607485PA (en) A method and system for enabling a payment
HK1231556A1 (zh) 確定組織放射敏感性的預測方法
IL260347A (en) Therapeutic antibodies against cd-9
HK1259331A1 (zh) 緊凑的流量計和相關方法
ZA201902933B (en) Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
HK1244314A1 (zh) 一種預測受試者的肥胖風險的方法
PL3259232T3 (pl) Sposób na aerożele
HUE049274T2 (hu) Eljárás és vezérlõkészülék jármû, különösen vasúti jármû üzemeltetésére
GB201516617D0 (en) Verification for payment transations
IL231685A (en) A system and method for predicting memory reduction and network design
IL231278A0 (en) A system to assist a needy person in transitioning between standing and sitting and between sitting and standing
GB201609084D0 (en) System for use in bioprocessing
SG10201603667WA (en) Methods and systems for making payments
GB201406223D0 (en) Method and system for facilitating a transaction
HK1223431A1 (zh) 用於優化儲存設備配置的系統及方法